Loading clinical trials...
Loading clinical trials...
A Single-Center, Phase 2a, Randomized, Double Masked, Clinical Study to Assess the Safety, Tolerability, and Pharmacodynamic Activity of ADX-102 Ophthalmic Solution in Subjects With Dry Eye Syndrome
Conditions
Interventions
ADX-102 Ophthalmic Solution (0.5%)
ADX-102 Ophthalmic Solution (0.1%)
+1 more
Locations
1
United States
Andover Eye Associates
Andover, Massachusetts, United States
Start Date
May 15, 2017
Primary Completion Date
July 6, 2017
Completion Date
July 6, 2017
Last Updated
January 16, 2025
NCT03135327
NCT02585414
NCT06848829
NCT06220474
NCT06291194
NCT04685109
Lead Sponsor
Aldeyra Therapeutics, Inc.
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions